Unanticipated Adverse Events With Tirzepatide: Three Cases Underscoring the Importance of Postmarketing Monitoring

Tirzepatide (Zepbound), a novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, demonstrates an additive effect, significantly enhancing insulin secretion compared to administering each hormone separately. The case reports presented here, detailing palpitations, musculoskeletal pain, and headaches following tirzepatide administration, raise important questions about the drug's postmarketing safety profile.